Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues.

Abstract

Cardiovascular diseases are the leading cause of death in people with diabetes. Diabetic cardiomyopathy (DC) is an important complication of diabetes and represents a distinct subtype of heart failure that occurs in absence of cardiovascular diseases. Chronic hyperglycemia and hyperinsulinemia along with insulin resistance and inflammatory milieu are the main mechanisms involved in the pathophysiology of DC. Changes in lifestyle favoring healthy dietary patterns and physical activity, combined with more innovative anti-diabetes therapies, are the current treatment strategies to safeguard the cardiovascular system. This review aims at providing an updated comprehensive overview of clinical, pathogenetic, and molecular aspects of DC, with a focus on the effects of anti-hyperglycemic drugs on the prevention of pump dysfunction and consequently on cardiovascular health in type 2 diabetes.

• Authors: Miriam Longo, Lorenzo Scappaticcio, Paolo Cirillo, Antonietta Maio, Raffaela Carotenuto, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito
• Journal: Biomolecules (Biomolecules) Vol. 12 Issue 2 (02 08 2022) ISSN: 2218-273X [Electronic] Switzerland
• PMID: 35204778 (Publication Type: Journal Article, Review)

Topics

• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Diabetic Cardiomyopathies (drug therapy)
• Glycemic Control
• Heart
• Humans
• Hyperglycemia (complications)